Worldwide, there are an estimated 33 million persons infected with HIV. Before starting AIDS patient on Highly Active Anti-Retroviral Therapy (HAART), one or more of the following criteria should be met: CD4 count < 500cells/mcl, rapidly dropping CD4 count, hepatitis B or C co-infection, the risk of cardiac disease, HIV nephropathy, increased risk for non-HIV related cancers. Five categories of drugs are used usually in combination; the Nucleoside reverse transcriptase Inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Protease inhibitors (PIs), Chemokine receptor antagonists (CCR5 antagonists) and integrase inhibitors (II). The objective of the study was to determine the frequency of anaemia in AIDS patients receiving Zidovudine based Anti-Retroviral Therapy. Total 209 patients were enrolled, 16.2% using Zidovudine based therapy for six months. Our study showed that among 209 patients mean age was 32 years with SD ± 3.51. Seventy-two percent patients were male while 28% patients were female. Mean HB level was 13 g/dl with SD ± 2.53. More over 20% patients were anaemic and 80% patients were not anaemic. Thus, this study concluded that the incidence of anaemia in AIDS patients receiving Zidovudine based Anti-Retroviral Therapy was found to be 20%.

Richman DD, Fischl MA, Grieco MH. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New English Journal of Medicine 317, 192-197.

Volberding PA, Lagakos SW, Koch MA. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trial Group of the National Institute of Allergy and Infectious Diseases. New English Journal of Medicine 322(14), 941-949.